Skip to main content

Table 1 Summary of studies used and disease/treatment group and treatment variables used in regression models

From: Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions

Name Short form Inclusion/Exclusion Criteria Study type Study size Cardiac subgroup Disease/
treatment groups (random effect)
Treatment
Cost-effectiveness of functional cardiac testing in the diagnosis and management of CHD [12] CECaT I: established or suspected CHD referred for angiography
E: recent MI, revascularization, urgent need for revascularization, contraindications to study tests
Diagnosis/
management (RCT)
898 Coronary disease diagnosis CECaT baseline
CECaT MM
CECaT PCI
CECaT CABG
Pre-treatment
MM
PCI
CABG
Appropriateness for coronary revascularization [1] ACRE I: Consecutive patients having coronary angiography
E: None
Diagnosis/
management (cohort)
2419 Coronary
revascularization
ACRE MM
ACRE PCI
ACRE CABG
MM
PCI
CABG
Implantable Cardioverter Defibrillator (ICD) therapy in different patient groups [28] ICD I: patients implanted with an ICD at Papworth or Liverpool hospitals between 1991 and 1999 and a random sample of those implanted in 2000 and 2001 Diagnosis/
management (cohort)
229 Cardiac arrythmias ICD ICD
Percutaneous myocardial revascularization (PMR) compared to continued medical therapy [29] PMR I: angina refractory to medication or revascularization
E: implanted devices, significant comorbidity, contraindications to study treatments
Angina (RCT) 73 Angina PMR Pre-treatment*
MM
PMR
Transmyocardial laser revascularization (TMR) compared to continued medical therapy [30] TMR I: angina refractory to medication or revascularization
E: implanted devices, significant comorbidity, contraindications to study treatments
Angina (RCT) 188 Angina TMR baseline
TMR MM
TMR
Pre-treatment*
MM
TMR
Spinal cord stimulation (SCS) compared to PMR [31] SPiRiT I: angina refractory to medication or revascularization
E: implanted devices, significant comorbidity, contraindications to study treatments
Angina (RCT) 68 Angina SPiRiT baseline
PMR
SCS
Pre-treatment*
PMR
SCS
Evaluation of ventricular assist devices (VAD) patients compared to patients on transplant waiting list (Tx WL) [3] Tx WL I: a sample of patients listed for transplant between April 2002 and December 2004 Heart failure (cohort) 47 Heart failure Tx WL Pre-treatment*
  VAD I: all patients with VADs implanted as part of NSCAG funded program between April 2002 and December 2004 Heart failure (cohort) 35 Heart failure VAD
Post-tx (post-transplant)
VAD
Tx
  1. Key: CHD - coronary heart disease, I - inclusion criteria, E - exclusion criteria, MI - myocardial infarction, RCT - randomised controlled trial, MM - medical management, PCI - balloon angioplasty/stenting, CABG - coronary artery bypass graft, NSCAG - National Specialist Commissioning Advisory Group
  2. *NB: Pre-treatment for that study, but these patients will not be treatment naïve.